NRx Pharmaceuticals, Inc. (NRXP)

1.6800 +0.0500 (+3.07%) As of 12:56PM EDT. Market open.

NRx Pharmaceuticals, Inc.

1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
(484) 254-6134
https://www.nrxpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jonathan C. Javitt M.D., M.P.H.	Co-Founder, Chief Scientist Officer & Chairman	630.2k	N/A	1957
Mr. Stephen H. Willard Esq.	Acting Corporate Secretary, CEO & Director	500k	N/A	1961
Mr. Richard Clavano Narido	CFO & Treasurer	255.01k	N/A	1979
Dr. Riccardo Panicucci Ph.D.	Chief Manufacturing & Technology Officer	240k	N/A	1961
Suzanne Messere	Investor Relations	N/A	N/A	N/A
Dr. Philip T. Lavin Ph.D.	Chief Methodologist	N/A	N/A	1947
Mr. Matthew Patrick Duffy	Chief Business Officer	N/A	N/A	1963

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Corporate governance

NRx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.